Published online Aug 7, 2021. doi: 10.3748/wjg.v27.i29.4862
Peer-review started: March 7, 2021
First decision: April 17, 2021
Revised: April 19, 2021
Accepted: July 19, 2021
Article in press: July 19, 2021
Published online: August 7, 2021
Processing time: 150 Days and 0.7 Hours
Sarcopenia is becoming a well-established player in evaluating patients with chronic liver disease. Data regarding its clinical significance and consequences in the course of liver disease have been growing; many of the data support the idea that it impacts decompensation event frequency, prolonged hospitalization, and mortality, as well as providing the possibility to better prioritize patients on lists awaiting liver transplantation. When assessing the whole clinical scope of the field, which includes malnutrition and frailty, as well as the complete spectrum of muscle mass, strength, and function, it becomes clear that a well-founded app
Core Tip: Knowledge regarding the influence of sarcopenia in the course of chronic liver disease has greatly expanded in the past ten years, especially with respect to cirrhosis. Data show that it has a great influence on disease decompensation and patient mortality, providing clues for the development of newer evaluation modalities and sarcopenia indices. Nonetheless, data regarding the therapeutic consequences and interventions remain scarce. This article attempts to summarize the current state of knowledge of this important clinical topic with a critical evaluation of some related groundbreaking studies.
